278 results about "Spiro compound" patented technology

The light emitting device of the present invention relates to a light emitting device which is characterized in that it is a device with an emissive substance present between an anode and cathode, and which emits light by means of electrical energy, and said device has a least one type of compound denoted by (a) to (d) below. (a) A compound having a plurality of 1,7-phenanthroline skeletal structures (b) A benzoquinoline derivative (c) A spiro compound represented by general formula (1) A1 and A2 are each selected from single bonds, substituted or unsubstituted alkyl chains, ether chains, thioether chains, ketone chains and substituted or unsubstituted amino chains. However, A1<> A2. Z represents carbon or silicon. R1 to R16 are each selected from hydrogen, alkyl group, cycloalkyl group, aralkyl group, alkenyl group, cycloalkenyl group, alkynyl group, hydroxyl group, mercapto group, alkoxy group, alkylthio group, aryl ether group, aryl thioether group, aryl group, heterocyclic group, halogen, haloalkane, haloalkene, haloalkyne, cyano group, aldehyde group, carbonyl group, carboxyl group, ester group, carbamoyl group, amino group, nitro group, silyl group, siloxanyl group and a cyclic structure formed with an adjacent substituent. (d) A tetraphenylmethane derivative represented by general formula (2) R17 to R36 are each selected from hydrogen, alkyl group, cycloalkyl group, aralkyl group, alkenyl group, cycloalkenyl group, alkynyl group, hydroxyl group, mercapto group, alkoxy group, alkylthio group, aryl ether group, aryl thioether group, aryl group, heterocyclic group, halogen, haloalkane, haloalkene, haloalkyne, cyano group, aldehyde group, carbonyl group, carboxyl group, ester group, carbamoyl group, amino group, nitro group, silyl group, siloxanyl group and a cyclic structure formed with an adjacent substituent. However, at least one of R17 to R36 is selected from substituents represented by general formula (3). -X-Ar (3) X is a single bond or is selected from the following, and Ar denotes a condensed aromatic ring or heteroaromatic ring. In the case where X is phosphorus oxide, then Ar represents an aromatic hydrocarbon or heteroaromatic ring. n is an natural number.

The present invention relates to a spiro-compound for an electroluminescence display device and an electroluminescence display device including the same. More particularly, the present invention relates to a spiro-compound comprising at least one selected from the group consisting of a compound represented as the following Formulae 1 and 2 and an electroluminescence display device including the same: In the above Formulae 1 and 2, the definition of the substituents is the same as in the specification. The spiro-compounds represented by the above Formulae 1 and 2 are applicable to any one of a hole injection layer (HIL), a hole transport layer (HTL), an electroluminescent layer, an electron transport layer (ETL), and an electron injection layer (EIL) of the electroluminescence display device. The spiro-compound can realize various colors with low energy, emit blue light even at a low voltage, and have an advantage of excellently increasing luminance and luminous efficiency.

The present invention relates to 1-oxa-3,8-diaza-spiro[4.5]decan-2-one compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease condition associated with a monoamine receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.

The present invention relates to spiroazacyclic compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease condition associated with a monoamine receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.

The present invention relates to a novel class of substituted spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and / or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and / or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.

The Spiro compound represented by the following general formula [Ia], its pharmaceutically acceptable salt or a solvate thereof

One aspect of the present invention relates to spirocyclic compounds. Another aspect of the present invention relates to the use of the spirocyclic compounds as ligands for mammalian G-protein-coupled receptors or sigma receptors. The present invention also relates to methods of modulating the activity of a G-protein-coupled receptor or a sigma receptor in a mammal using the spirocyclic compounds of the present invention. The present invention also relates to methods of treating various diseases in a mammal using the spirocyclic compounds of the present invention.

Disclosed is an electric double layer capacitor that comprises: a polarizable electrode containing a carbon material having graphite-like microcrystalline carbon; and an electrolyte containing a spiro compound represented by the general formula(where A represents a spiro atom having an sp3 hybrid orbital, Z1 and Z2 each represent a group of atoms forming a saturated ring or unsaturated ring in which the number of ring atoms including A is four or more, and X− represents a counter-anion). According to the present invention, an electric field activation type electric double layer capacitor can be obtained that simultaneously achieves improved volumetric capacitance density, improved resistance, and improved withstand voltage.

The invention relates to a spiro compound serving as a FXR receptor agonist, whose chemical structure is shown in type I, pharmaceutically acceptable salts of the spiro compound, or the enantiomers, diastereomers, tautomers, racemates, solvates, N-oxide or amino acid conjugates and the pharmaceutical compositions of the spiro compound, and the use in preparing drugs for treatment of diseases mediated by the FXR receptor.

The invention provides a copolyester thermoplastic material used for three-dimensional printing and preparation and application thereof. The copolyester thermoplastic material is mainly prepared from monomers of the raw materials consisting of, by mass, 35 to 48 parts of dicarboxylic acid, 30 to 43 parts of dihydric alcohol, 8 to 15 parts of acrylate and 7 to 15 parts of a spiro-compound through copolymerization in the presence of a catalyst. The invention has the following main beneficial effects: the copolyester high-molecular material prepared in the invention has good mechanical properties and machinability, is a good thermoplastic material and has a wide application scope; high temperature resistance and moisture resistance of the material are substantially improved compared with those of traditional products, and the material has good weatherability; the material has small shrinkage, adhesion among different layers is strong, a product manufactured from the material does not suffer interlayer stripping and warping, so the material is an ideal three-dimensional printing material and is especially applicable to fused deposition modeling (FDM) technology.

A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11 β-hydroxy-Steroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.

The present invention is directed to compounds having the formula (I): useful in treating inflammatory and immune diseases, in which K and L are independently, O or S; Q is —C(═O)— or optionally substituted C1-6alkylene; Ar is optionally-substituted aryl or heteroaryl; J1, J2, J3 and Y are selected so that ring A is a five-to-six membered optionally-substituted cycloalkenyl or heterocyclo ring having 0 to 2 nitrogen heteroatoms; R1 is N or C(R9); and R2, and R3, are as defined in the specification.

Provided are a novel spiro compound, and an organic luminescence device using the spiro compound and having an optical output with an extremely high efficiency and a high luminance, and an extremely high durability. The Spiro compound is represented by the following general formula [I]: (wherein R1, R2, R3, and R4 represent a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic group, a substituted amino group, a cyano group, or a halogen atom, and R1, R2, R3, and R4 may be identical or different from each other; and Ar1 and Ar2 represent a substituted or unsubstituted condensed polycyclic aromatic group or a substituted or unsubstituted condensed polycyclic heterocyclic group, which may be identical or different from each other.)

The present invention relates to certain spirocyclic compounds that are inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 (11βHSD1), compositions containing the same, and methods of using the same for the treatment of diabetes, obesity and other diseases.

An electrolytic solution for electric double layer capacitor characterized in that a Spiro compound of formula (1) is contained as an electrolyte in an aprotic solvent and that the electric conductivity thereof at −40° C. is 0.85 mS / cm or higher. This electrolytic solution for electric double layer capacitor realizes a high dissolution of electrolyte in solvent and exhibits excellent conductivity and electrostatic capacity over a wide temperature range from low temperature to high temperature. Further, the electrolytic solution for electric double layer capacitor exhibits high resistance to voltage and even under long-term high voltage load, exhibits suppressed lowering of electrostatic capacity to thereby excel in long-term stability.

In an organic luminescence device formed of one or plural layers of organic films between an anode and a cathode, at least one layer is any one of a luminescence layer, an electron injection layer and an electron-transporting layer and is formed of at least a spiro compound of formula (I-a) or (I-b) having a carbon atom or a silicon atom as a spiro atom and having four ring structures including at least one nitrogen atom-containing ring structure. By the use of the spiro compound of the formula (I-a) or (I-b), the resultant organic luminescence device produces a high-luminance fluorescent luminescence at a low voltage for a long period of time.

The present invention aims to provide a novel SCD inhibitor.The present invention relate to SCD inhibitor comprising A compound represented by the formula (I)whereinR is an optionally substituted cyclic group or an optionally substituted carbamoyl group, provided that R is not an optionally substituted 7-pyrido[2,3-d]pyrimidyl group;ring A is an optionally further substituted pyridazine ring;R1, R2, R3, R4, R11, R12, R13 and R14 are each independently a hydrogen atom or a substituent, or R1 and R11 in combination, R2 and R12 in combination, R3 and R13 in combination, or R4 and R14 in combination optionally form an oxo group, or R2 and R4 in combination optionally form a bond or an alkylene cross-linkage;m and n are each independently an integer of 0 to 2;ring B is an optionally substituted ring, provided that the two atoms constituting ring B, which are adjacent to the spiro carbon atom, are not oxygen atoms at the same time, or a salt thereof, or a prodrug thereof.

The invention relates to application of a solvent photochromic spiro compound. The application of the solvent photochromic spiro compound is characterized by being the application caused along with color change after the spiro compound generates screw carbon-heteroatomic covalent bond fracture under solved participated stimulation and the screw carbon-heteroatomic covalent bond is regenerated under another external stimulation. The spiro compound with such a property has three structure general formulas (shown in drawing 1 of the abstract). Color change of the spiro compound under solved participated stimulation can be used for bringing about wide applications, such as potential application in the fields of a solvent property indicator, solvent component detection, safety ink, writing paper, inkless printing and the like.

An organic luminescence device is formed by disposing a layer of organic compound between a pair of an anode and a cathode. An organic luminescence device exhibiting orange to red luminescence at a good durability is provided by including an organic compound layer containing a spiro compound selected from a specific class, e.g., one represented by the following structural formula: wherein Rx represents

The invention belongs to the technical field of drug synthesis. In order to solve the reactions involved in the preparation of diazaspiro compounds in the prior art, there are disadvantages such as requiring some relatively expensive reagents and requiring low temperature for operation. The invention provides a method for preparing diazaspirocyclic compounds. The method of the spiro compound, the diaza spiro compound has the structure of formula I or formula VI, the method uses the compound formula V as the initial raw material, comprising: a, removing the No. 1 position in the compound formula V with a proton-removing reagent and then carry out alkylation reaction with the saturated chain alkane formula III with halogenation at both ends to form the first intermediate product formula II; b, replace the carbon at the 2nd position in the first intermediate product formula II with an azide reagent On the halogen X2, form the second intermediate product formula IV; c, carry out reduction ring closure reaction on the second intermediate product formula IV, form the diaza spiro compound formula I; d, carry out the diaza spiro compound formula I Reduction gives the diaza spiro compound formula VI.

An organic luminescence device is formed by disposing a layer of organic compound between a pair of an anode and a cathode. An organic luminescence device exhibiting orange to red luminescence at a good durability is provided by including an organic compound layer containing a spiro compound selected from a specific class, e.g., one represented by the following structural formula:wherein Rx represents

The present invention discloses a trifluoromethyl containing quinazoline derivative and a preparation method and application thereof. The preparation method comprises the following steps of: under the condition that copper and ligand exist, an N-cyano substituted aryl carboxamides compound reacting with a togni reagent in a solvent, and after completion of the reaction, obtaining the trifluoromethyl containing quinazoline derivative after treatment. The reaction substrate is readily available, the operation is convenient, the obtained quinazolinone derivative is of rich diversity, the required reaction condition is mild, and the reaction time is short. The all-in-one-pot reaction is realized, and not only a structural mother kernel of quinazoline is obtained, but also trifluoromethyl is introduced into the mother kernel structure. And the quinazolinone compound contains the spiropyran compound can be synthesized, which cannot be achieved by the prior art. The obtained product has good activity in inhibiting enzyme acetylcholinesterase and butyrylcholinesterase.